BAT2606 (mepolizumab biosimilar)
/ Bio-Thera Solutions
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 28, 2023
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
(clinicaltrials.gov)
- P1 | N=207 | Completed | Sponsor: Bio-Thera Solutions | Active, not recruiting ➔ Completed
Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
May 09, 2023
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
(clinicaltrials.gov)
- P1 | N=207 | Active, not recruiting | Sponsor: Bio-Thera Solutions | Trial primary completion date: Feb 2023 ➔ Jun 2023
Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
February 06, 2023
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
(clinicaltrials.gov)
- P1 | N=207 | Active, not recruiting | Sponsor: Bio-Thera Solutions | Recruiting ➔ Active, not recruiting
Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
October 12, 2022
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
(clinicaltrials.gov)
- P1 | N=207 | Recruiting | Sponsor: Bio-Thera Solutions
New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1